Immune & cellular health / VISUAL FIELD GUIDE

SS-31 / Elamipretide

SS-31, or elamipretide, targets mitochondrial membrane biology. It now has a specific US accelerated approval for Barth syndrome, which is separate from general longevity use.

Explore in the human body ↗

01 / FOLLOW THE BIOLOGY

From signal to response.

Schematic explanation · not a measured treatment response

STEP 1 OF 3

Inner membrane

The molecule interacts with a mitochondrial membrane lipid.

Pathway sources: [1] [2]

02 / SYMPTOMS & STUDIED USES

What are you trying to understand?

Choose a concern to see the research context. A symptom is a starting point for assessment, not a treatment selection.

Specific US accelerated approval

Barth syndrome / muscle weakness

Forzinity is approved to improve muscle strength in patients with Barth syndrome weighing at least 30 kg; confirmatory evidence remains required.

Examine the supporting research ↓

03 / KEEP THE CONTEXT

The details that change the interpretation.

Formulation & route

Evidence and approval for Forzinity do not establish equivalence of compounded “SS-31” pens.

Bring to the discussion

Does the person have the studied disease and is this the same product?

04 / SOURCE TRAIL

Go beyond the summary.

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

pubmed.ncbi.nlm.nih.gov · Open source ↗

FDA approval announcement

www.fda.gov · Open source ↗

More research already linked in Kamura (1)

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. · 2021